As for the reason why MYBL2 expression appeared to have no relationship with CD8 + T cells in clinical tissue, we hypothesize that tumor progression in patients involves a complex regulation network and other pathways may affect the abundance of CD8 + T cells in the microenvironment with low MYBL2 expression. This evidence concerns the gene CD8A and neoplasm.